Title |
Profile of efraloctocog alfa and its potential in the treatment of hemophilia A
|
---|---|
Published in |
Journal of Blood Medicine, April 2015
|
DOI | 10.2147/jbm.s54632 |
Pubmed ID | |
Authors |
Lindsey A George, Rodney M Camire |
Abstract |
Hemophilia care has improved dramatically over the past 50 years, evolving from plasma concentrates, to purified plasma proteins, to recombinant clotting factors. These collective developments allowed for home delivery of on-demand and prophylactic treatment, resulting in the reduction of hemophilia morbidity and mortality and improved quality of life. Although efficacious in treating bleeding, conventional factor products' half-lives require frequent venipuncture, which remains a significant burden to patients. Despite the remarkable advances in hemophilia care, no improvements have, until now, been made to the pharmacokinetic properties of factor products. Multiple strategies have more recently been employed to generate novel bioengineered products that, with great hope, represent the next wave of progress in hemophilia care. The use of these products will undoubtedly raise important discussion about choosing conventional factor over new long-acting factor products. Incorporation of these therapies into clinical care is accompanied by unanswered safety questions that will likely be evaluated only in postmarketing surveillance analysis. Further, these products may change current treatment paradigms with unclear cost repercussions and feasibility. This paper will review efraloctocog alfa (FVIII-Fc) and its role in the treatment of hemophilia A. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 21 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 2 | 10% |
Student > Ph. D. Student | 2 | 10% |
Professor | 1 | 5% |
Unknown | 16 | 76% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
Biochemistry, Genetics and Molecular Biology | 1 | 5% |
Nursing and Health Professions | 1 | 5% |
Social Sciences | 1 | 5% |
Medicine and Dentistry | 1 | 5% |
Other | 0 | 0% |
Unknown | 16 | 76% |